Blog
RSS FeedPosted by Michael Wonder on 10 Mar 2021
AVEO Oncology announces U.S. FDA approval of Fotivda (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma
10 March 2021 - AVEO plans to make Fotivda available to patients in the U.S. by 31 March 2021. ...
Posted by Michael Wonder on 10 Mar 2021
Vertex announces FDA fast track designation and initiation of a Phase 1/2 clinical trial for VX-880, a novel investigational cell therapy for the treatment of type 1 diabetes
10 March 2021 - VX-880 is the first investigational stem cell derived therapy utilising fully differentiated, insulin-producing pancreatic islet cells for ...
Posted by Michael Wonder on 10 Mar 2021
FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
10 March 2021 - The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on ...
Posted by Michael Wonder on 10 Mar 2021
Australia’s Therapeutic Goods Administration approves Feraccru to treat iron deficiency with or without anaemia in adults
9 March 2021 - Shield Therapeutics notes that Australia’s Therapeutic Goods Administration has registered Feraccru in the Australian Register of ...
Posted by Michael Wonder on 10 Mar 2021
U.S. FDA accepts UVision360 submission for novel Luminelle DTx system biopsy sheath
9 March 2021 - UVision360 announces today that the U.S. FDA has accepted the Company's submission to expand the Luminelle DTx ...
Posted by Michael Wonder on 10 Mar 2021
TGA approves Zolgensma
10 March 2021 - Onasemnogene abeparvovec is a new gene therapy for children with spinal muscular atrophy. ...
Posted by Michael Wonder on 10 Mar 2021
Developers of Russian Sputnik V vaccine doubt EU regulator's neutrality, want apology
9 March 2021 - The developers of Russia’s Sputnik V vaccine against COVID-19 on Tuesday questioned the EMA's neutrality, after ...
Posted by Michael Wonder on 09 Mar 2021
Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy designation for RP-L201 gene therapy for leukocyte adhesion deficiency-I
9 March 2021 - Enrollment complete in Phase 1/2 clinical trial of RP-L201 for the treatment of LAD-I. ...
Posted by Michael Wonder on 09 Mar 2021
Seqirus announces U.S. FDA approval of expanded age indication of its cell based quadrivalent influenza vaccine for people two years of age and older
5 March 2021 - Seqirus today announced that the U.S. FDA has approved Flucelvax Quadrivalent (influenza vaccine), the company's cell-based quadrivalent ...
Posted by Michael Wonder on 09 Mar 2021
Biden’s silence on an FDA nominee underscores how tough it is to fill that job
9 March 2021 - Nearly everyone here expected President Biden to move with record speed to nominate someone to lead ...
Posted by Michael Wonder on 09 Mar 2021
Pandemic forces FDA to sharply curtail drug company inspections
9 March 2021 - The steep decline in oversight has stalled a number of new drug applications. ...
Posted by Michael Wonder on 09 Mar 2021
Acadia Pharmaceuticals provides regulatory update on supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis
8 March 2021 - Acadia Pharmaceuticals today announced that the Company received a notification from the U.S. FDA on 3 March ...
Posted by Michael Wonder on 09 Mar 2021
Roche receives FDA approval for Ventana ALK (D5F3) CDx assay to identify lung cancer patients eligible for targeted treatment with Lorbrena (lorlatinib)
9 March 2021 - The Ventana ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted ...
Posted by Michael Wonder on 09 Mar 2021
AltruBio’s neihulizumab granted fast track designation by the FDA for steroid refractory acute graft versus host disease
8 March 2021 - AltruBio announced today that the U.S. FDA granted fast track designation for its immune checkpoint regulator, ...
Posted by Michael Wonder on 09 Mar 2021
Sesen Bio submits marketing authorisation application to the European Medicines Agency for Vicineum
8 March 2021 - Potential approval in Europe anticipated in early 2022. ...